Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/09/16
End: 09/30/16
Due: 09/30/17
Phase: N/A
Priority: Normal
Start: 01/11/18
End: 01/15/21
Due: 01/15/22
Phase: N/A
Priority: Normal
Start: 02/05/20
End: 12/22/20
Due: 12/22/21
Phase: N/A
Priority: Normal
Start: 01/18/22
End: 08/24/22
Due: 08/24/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Alteogen, Inc. | user2@example.com | None | 2016-02-09 | 2016-09-30 | 2017-09-30 | - | - | 2025-07-14 |
| Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients | NCT03281824 | Alteogen, Inc. | user2@example.com | None | 2018-01-11 | 2021-01-15 | 2022-01-15 | - | - | 2025-07-14 |
| Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD | NCT04058535 | Alteogen, Inc. | user2@example.com | None | 2020-02-05 | 2020-12-22 | 2021-12-22 | - | - | 2025-07-14 |
| Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer | NCT05232175 | Alteogen, Inc. | user2@example.com | None | 2022-01-18 | 2022-08-24 | 2023-08-24 | - | - | 2025-07-14 |